|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Prognostic evaluation of postoperative adjuvant therapy for operable cervical cancer:10 years'experience of National Cancer Center in China显示文摘Objective: The aim of this study was to investigate the prognostic factors and to evaluate the impact of adjuvant therapy on clinical outcome for early-stage cervical cancer.Methods: The clinical-pathological data of all 1,335 patients with the International Federation of Gynecology and Obstetrics(FIGO) Ib–IIa cervical cancer treated with primary radical surgery at the Chinese National Cancer Center between May 2007 and Dec 2013 were retrospectively reviewed.The median follow-up was 70 months.Results: Of all the patients,61.6% of the cases received adjuvant therapy,with 5-year disease-free survival(DFS)of 92.1% and 5-year overall survival(OS) of 95.0%.In multivariate analysis,differentiation of G3(P<0.05),lymph node metastasis(LNM,P<0.05) and lymphovascular space invasion(LVSI,P<0.05) were independent predictors for OS,while LNM(P<0.05),deep stroma invasion(DSI,P<0.05) and LVSI(P<0.05) were independent factors for DFS.The samples were stratified by histologic type,and cervical squamous cell carcinoma(SCC) was found to share the same independent factors except for differentiation of OS.As to patients with cervical adenocarcinoma/adenosquamous carcinoma(AC/ASC),differentiation was the independent predictor of OS(P<0.05); and LVSI of DFS(P<0.05).Of 236 patients with high-risk factors,there was no significant difference in survival between concurrent chemoradiotherapy(CCRT,n=195),radiotherapy(RT,n=24),and chemotherapy(CT,n=17).Among the 190 patients with LNM who underwent CCRT,124 cases showed improved DFS after sequential CT(P=0.118),with a recurrence rate decrease of 14%,though the difference was not statistically significant.Patients with single intermediate-risk factors like DSI or LVSI were found to partially benefit from adjuvant therapy,but the difference was not statistically significant.Conclusions: LNM,LVSI,DSI and differentiation were found to be independent prognostic factors for operable cervical cancer.Aggressive postoperative adjuvant therapy based on single risk factors in Chinese National Cancer Center could benefit survival.CCRT+CT outperformed CCRT in high-risk patients.For patients with single non-high-risk factor,the role of adjuvant therapy needs to be further discussed. | Tong Shu Dan Zhao Bin Li Yating Wang Shuanghuan Liu Pingping Li Jing Zuo Ping Ba i RongZhang Lingying Wu | 2017 | Chinese Journal of Cancer Research2017，29，6： | 12 |
| 2 | Nomograms based on HPV load for predicting survival in cervical squamous cell carcinoma: An observational study with a longterm follow-up显示文摘Objective: To investigate the prognostic value of pretreatment human papillomavirus(HPV) viral load for cervical cancer, and to develop nomograms based on HPV load and other clinicopathological factors for long-term survival.Methods: We conducted a prospective study on cervical squamous cell carcinoma(SCC) patients diagnosed between January 2003 and December 2008. Cervical samples were tested for HPV viral load by the Hybrid Capture II(HCII) assay before treatment and 6 months after treatment. Clinical characteristics and follow-up information were also collected. A multivariable Cox proportional hazards model was used to adjust covariates in both the radical hysterectomy(RH) treatment group and concurrent chemoradiotherapy(CCRT) treatment group to identify relevant covariates, and then nomograms were constructed and used for internal validation.Results: A total of 520 SCC patients enrolled in this study with a median follow-up of 127 months, 360 patients received RH, whereas 160 patients received CCRT. The median HPV viral load in RH and CCRT groups was356.10 and 294.29, respectively. Tumor size was positively correlated with high pretreatment HPV load in both groups. In CCRT group, the advanced International Federation of Gynecology and Obstetrics(FIGO) stage and enlarged retroperitoneal lymph node status determined by computed tomography(LNSCT) were correlated with low HPV load group. Initial HPV viral load, FIGO stage and lymph node metastasis were prognostic factors for RH group, whereas HPV viral load, squamous cell carcinoma antigen(SCC-Ag) level and LNSCT were identified as prognostic factors for CCRT group. Nomograms incorporating these predictors for 10-year progression-free survival(PFS) were constructed [concordance index(C-index): 0.756, 0.749].Conclusions: A low pretreatment HPV viral load is an independent prognostic factor for poor prognosis of cervical SCC and is related to other clinicopathological factors. The survival nomogram based on HPV viral load could predict the long-term prognosis. | Jing Zuo Ying Huang Jusheng An Xi Yang Ning Li Manni Huang Lingying Wu | 2019 | Chinese Journal of Cancer Research2019，31，2： | 4 |
| 3 | Papillary serous carcinoma of the uterine cervix:a clinicopathological analysis of 4 cases and a literature review显示文摘Objective To investigate the clinicopathological characteristics and clinical treatment outcomes of patients with papillary serous carcinoma of the uterine cervix(PSCC).Methods In this study, 4 patients with histologically confirmed papillary serous carcinoma of the uterine cervix were retrospectively investigated. Pap smears, human papillomavirus(HPV) screening, tumor marker status, biopsy analysis, and relevant imaging examinations were conducted for the confirmation of primary diagnosis and recurrence. Patients underwent surgery, chemotherapy, or radiotherapy, and survival were the main endpoint.Results The 4 patients were diagnosed with IB1, IB1, IIA, or IIIB disease. Two patients(2/4) presented with recurrence within 18 months after primary therapy. Compared with chemotherapy alone(progressionfree survival(PFS): 11 months), radiotherapy combined with adjuvant chemotherapy showed favorable PFS rates(PFS: 20, 36, 13 months in 3 cases), although valid statistical analysis was not feasible because of the small sample size. The 5-year survival rate was 0%, and the 3-year survival rate was 75%. Our data, in agreement with the literature evidence, showed that the number of moderate-risk and high-risk factors in patients diagnosed with PSCC at an early stage was higher than that in patients diagnosed with common adenocarcinoma/squamous carcinoma of the uterine cervix.Conclusion PSCC has a poor clinical prognosis, and compared with chemotherapy alone, radiotherapy combined with adjuvant chemotherapy may lead to improved PFS. | Li Ge Hongwen Yao Rong Zhang Xiaoguang Li Lingying Wu | 2017 | Oncology and Translational Medicine2017，3，5： | 2 |
| 4 | Synchronous primary cancers of the endometrium and ovary: review of 43 cases显示文摘目的将调查子宫内膜和卵巢的同步原发癌的临床、病理学的特征,治疗方法,和预后。有子宫内膜和卵巢的同步原发癌的 43 个病人的临床的数据回顾地被考察的方法。幸存被 Kaplan-Meier 方法计算并且比较了使用木头等级测试。结果在诊断的病人的中部的年龄是 49 年(范围, 28 73 年) 。最普通的症状是反常阴道流血(69.8%) 并且腹或骨盆的疼痛(44.2%) 。骨盆的群众在 39.5% 病人被发现并且在药品检查在 27.9% 扩大了宫体,当骨盆的群众在 43 个病人(29 个案例) 中的 67.4% 个被发现并且变厚时或在 23.3% 的反常子宫内膜(10 个案例) 在超声检查期间。CT/MRI 检查的 25 个病人,骨盆的群众在 13 种情况中被发现并且在 11 种情况中扩大了子宫。经历了子宫内膜的活体检视的所有 15 个病人被证明有子宫内膜样癌。浆液 CA125 水平被发现与中部的价值在 34 个检验盒子(64.7%) 中的 22 个中被提高 500 U/mL (范围, 39 3439 U/mL ) 。子宫内膜的癌的 FIGO 阶段:IA 18 盒子, IB 20 盒子, IC 2 盒子,和 IIA 3 盒子;卵巢的癌的阶段:IA 19 大小写, IB 4 盒子, IC 7 盒子, II 4 盒子,和 IIIC 9 盒子。24 个病人(55.8%) 在舞台我子宫内膜、卵巢的癌。同时, 31 个病人与网膜切除术和阑尾切除术加双边的输卵管卵巢切除术经历了全部的子宫切除 12 个病人有骨盆的淋巴节点解剖。43 个病人(88.4%) 中的 38 个有一病理地证明的子宫内膜的腺癌。占优势的卵巢的组织学与子宫内膜样部件是子宫内膜样或混合瘤(30/43, 69.8%) 。手术后地, 26 个病人(60.5%) 独自收到了辅助化疗,加放射疗法的 12 有的化疗,仅仅一个病人有独自一个的放射并且留下 4 个盒子没收到辅佐疗法。这个组的 3 年、 5 年的幸存率分别地是 87.4% 和 71.1% 。有子宫内膜样癌在的病人的 3 年、 5 年的幸存率子宫内膜、卵巢比有 non-endometrioid 的那些的高或混合了 histologic 子类型(93.8% , 82% 对 79.7% , 69%) 。有早阶段疾病的病人的 3 年、 5 年的幸存率比另外的病人的那些好(93.3% , 93.3% 对 69.7% , 36.7%) 。复发在 15 个病人(34.9%) 发展了。它被降低加放射疗法的化疗显著地并且断然影响了的 CA125 水平,早 FIGO 阶段,和助手的 univariate 分析显示出 5 年的幸存评价,当加放射疗法的仅仅早的 FIGO 舞台和化疗被揭示由时多变量分析同样独立的预示的因素。子宫内膜和卵巢的结论同步原发癌与也不同主要子宫内膜或卵巢的癌症,当通常它能与好预后在早舞台被检测时。进一步的预后需要上的 CA125 水平的影响学习了。外科治疗可能独自为早阶段病人是足够的。化疗正放射疗法可能为先进病人是必要的。 | Shaokang Ma Hongtu Zhang Yangchun Sun Lingying Wu | 2009 | The Chinese-German Journal of Clinical Oncology2009，8，2： | 2 |
| 5 | A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections显示文摘 | Peng Liu Yan Qin Lingying Wu Sheng Yang Nan Li Haijun Wang Haiyan Xu Kelin Sun Shuxiang Zhang Xiaohong Han Yan Sun Yuankai Shi | 2014 | Anti-Cancer Drugs2014，，4： | 1 |
| 6 | 子宫颈癌放疗后子宫体恶性肿瘤47例临床分析(英文)显示文摘Objective: To study the characteristics and clinical features of uterine neoplasms developed after radiation therapy for cervical carcinoma. Methods: Clinical data of 47 cases of uterine neoplasms occurred following radiation therapy for cervical carcinoma were retrospectively reviewed. Results: The median age at uterine neoplasms diagnosis was 62 years (range: 38–77 years), and the median latency period from initial therapy to development of uterine neoplasms was 14 years (range: 5–35 years). Thirty of 47 cases were endometrial carcinoma, of which 3 were uterine papillary serous carcinoma (UPSC). Seventeen of 47 patients were uterine sarcoma, all of those were carcinosarcoma. The distribution by stage, grade, and histology of 30 cases of endometrial carcinoma was as follows: stage Ib, 1 case; stage Ic, 2 cases; stage II, 6; stage IIIa, 4; stage IIIb, 2; stage IIIc, 11; stage IV, 4 cases; grade 1, two cases; grade 2, nine; grade 3 (include 3 UPSC patients), seventeen; unknown grade, two; endometriod, 27; UPSC, 3 cases; 7 of 30 cases of endometrial carcinoma had recurrences (23.3%), at median time to recurrence was 24 months, and their median survival time was 26 months. The overall 3and 5-year survival rates were 60% and 38%, respectively. Of the 17 cases of uterine sarcoma, the median survival was 10 months, 6 patients occurred recurrence (35.9%), at a median time to recurrence was 9 months, and their median survival was 6 months. The overall 3and 5-year survival rates were 12% and 0, respectively. Conclusion: The main uterine neoplasms development after radiation therapy for cervical carcinoma is endometrial carcinomas, of which there is a preponderance of high-risk histological subtypes and a poor prognosis. Most of the uterine sarcomas occurred following radiation therapy for cervical carcinoma are carcinosarcomas and the prognosis is very poor. | Shaokang Ma Lingying Wu | 2009 | The Chinese-German Journal of Clinical Oncology2009，8，6： | 1 |
| 7 | Anti-leukemia activity of PVP-coated silver nanoparticles via generation of reactive oxygen species and release of silver ions显示文摘 | Dawei Guo Lingying Zhu Zhihai Huang Haixia Zhou Yue Ge Wenjuan Ma Jie Wu Xiuyan Zhang Xuefeng Zhou Yu Zhang Yun Zhao Ning Gu | 2013 | Biomaterials2013，，： | 1 |
| 8 | Transgenic expression of IL-33 activates CD8 + T cells and NK cells and inhibits tumor growth and metastasis in mice显示文摘 | Kun Gao Xiaoying Li Li Zhang Lin Bai Wei Dong Kai Gao Guiying Shi Xianzhu Xia Lingying Wu Lianfeng Zhang | 2013 | Cancer Letters2013，，2： | 1 |
| 9 | Comparison of two methods for evaluating lower urinary tract symptoms in cervical cancer patients following radical hysterectomy显示文摘Objective:To compare the degree of agreement and consistency of urodynamic studies(UDS)with low urinary tract symptoms(LUTS)questionnaires for evaluating LUTS in cervical cancer patients following radical hysterectomy(RH)and pelvic lymphadenectomy.Methods:From January 2012 to March 2015,204 cervical cancer patients who underwent RH in 13 hospitals were evaluated using the Incontinence Questionnaire-Female Lower Urinary Tract Symptoms(ICIQ-FLUTS)and the Overactive Bladder Symptom Score(OABSS).Urodynamic tests were also performed on these patients during the same period.Results:Study participants’age ranged from 23 to 75 years,with a mean(standard deviation)of 48.0±9.3 years.Using questionnaires,the prevalence of patients with LUTS symptoms,including storage symptoms,voiding symptoms,stress urinary incontinence(SUI)and overactive bladder(OAB)was 86.3%,77.0%,62.7%,52.9%and 14.7%,respectively.For UDS,the corresponding prevalence was 89.7%,70.1%,66.7%,46.6%and 13.2%,respectively.The diagnostic concordance of questionnaires and UDS for storage symptoms,voiding symptoms,SUI and OAB was 79.9%,66.7%,66.7%,57.4%and 79.9%,respectively.For voiding symptoms,the correlation coefficient was 0.272,which was higher than that of storage symptoms,SUI and OAB. | Fang An Sha Wang Zhiqi Wang Lingying Wu Qiubo Lv Aiming Lv Hongwu Wen Jinsong Han Yumei Wu Yunong Gao Qing Liu Sumei Wang Hongxia Li Luwen Wang Yanlong Wang Ruifang Wu Huan Li Xiuli Sun | 2021 | Gynecology and Obstetrics Clinical Medicine2021，1，2： | 0 |
| 10 | Pegylated Liposomal Doxorubicin as a Single Agent or as Combination Therapy with Carboplatin in Patients with Recurrent or Refractory Epithelial Ovarian Cancer显示文摘OBJECTIVE Pegylated liposomal doxorubicin (PLD;CAELYX^(?)), a novel formulation of doxorubicin with enhancedtherapeutic efficacy and reduced toxicity, has demonstratedimproved progression-free survival in recurrent or refractoryovarian cancer. The objective of this open-label, noncomparative,observational study was to determine the efficacyand safety of PLD monotherapy or combination therapy withcarboplatin for patients with recurrent or refractory ovariancancer.METHODS Sixty-two patients with recurrent or refractoryovarian cancer who completed a platinum-based chemotherapyregimen and demonstrated platinum sensitivity for first-linetreatment at least 6 months prior to study entry were enrolledin 20 centers in China. PLD was given as monotherapy (50mg/m^2 infused over 60 minutes) or as combination therapy(30 mg/m^2 1-hour infusion) with carboplatin (area under thecurve 5 mg.min/mL 1-hour infusion) on day 1 every 28 daysfor 4 cycles. The primary endpoint was objective response (OR)rate or CA-125 level. Secondary endpoints included time toresponse, time-to-progression, health-related quality of life, andsafety.RESULTS Overall, 48% of the 62 evaluable patients achieveda confirmed OR. More patients receiving PLD and carboplatinachieved an OR vs the PLD monotherapy group (63% vs. 37%).The median time to response and disease progression was58.5 days and 56.0 days, respectively. Overall and drug-relatedadverse events were reported for 39% and 34%, respectively.The most commonly reported adverse events were stomatitis(22.6%) and palmar-plantar erythroderma (9.7%). Two deathswere reported.CONCLUSION PLD is an effective and well tolerated agentin women with recurrent or refractory epithelial ovarian cancer. | Beihua Kong Yunong Gao Lingying Wu Ziting Li Yile Chen Mengda Li Yongliang Gao Ding ga Zhilan Peng KengShen | 2009 | Clinical oncology and cancer resexreh2009，6，6： | 0 |
| 11 | Down-Modulation of Notch1 Expression in Cervical Cancer Is Associated with HPV-Induced Carcinogenesis显示文摘OBJECTIVE Notch1 signaling has been implicated intumorigenesis. The purpose of this study was to investigate theputative role of the Notch1 receptor in carcinogenesis and in theprogression of the cervical cancer. Since human papillomavirus(HPV) is a causative agent in cervical carcinoma, the interactionbetween Notch1 and HPV infection was examined.METHODS Forty cervical cancer samples and 30 normalcervical tissue specimens were examined using Western blot andRT-PCR to detect Notch1 protein and mRNA levels. HPV16 DNAwas examined in all samples using PCR.RESULTS The level of Notch1 protein expression wassignificantly lower in cervical cancer tissue than in normal tissue.Levels of Notch1 mRNA were found to be substantially downregulatedin cancer tissue. Notch1 protein expression levelswere significantly higher in carcinomas without HPV DNAthan that in carcinomas with HPV infection (55.5% vs. 3.3%, P <0.05). Down-modulation of Notch1 mRNA levels in carcinomawas demonstrated to be associated with HPVE6 transcription.Moreover, levels of Notch1 expression were shown to besignificantly higher in early stage disease than in advanced stagedisease (P = 0.001).CONCLUSION Down-modulation of Notch1 expressionprobably plays an important role in the late stages of HPVinducedcervical cancer. | Li Sun Yongmei Song Tong Tong Lingying Wu Wenhua Zhang Qimin Zhan | 2009 | Clinical oncology and cancer resexreh2009，6，6： | 0 |
| 12 | A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors显示文摘Poly(ADP-ribose)polymerase(PARP)inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination(HR)deficiency.However,many patients without apparent HR defects also respond well to PARP inhibitors/cisplatin.The biomarker responsible for this mechanism remains unclear.Here,we identified a set of ribosomal genes that predict response to PARP inhibitors/cisplatin in HR-proficient patients.PARP inhibitor/cisplatin selectively eliminates cells with high expression of the eight genes in the identified panel via DNA damage(ATM)signaling-induced pro-apoptotic ribosomal stress,which along with ATM signaling-induced pro-survival HR repair constitutes a new model to balance the cell fate in response to DNA damage.Therefore,the combined examination of the gene panel along with HR status would allow for more precise predictions of clinical response to PARP inhibitor/cisplatin.The gene panel as an independent biomarker was validated by multiple published clinical datasets,as well as by an ovarian cancer organoids library we established.More importantly,its predictive value was further verified in a cohort of PARP inhibitor-treated ovarian cancer patients with both RNA-seq and WGS data.Furthermore,we identified several marketed drugs capable of upregulating the expression of the genes in the panel without causing HR deficiency in PARP inhibitor/cisplatin-resistant cell lines.These drugs enhance PARP inhibitor/cisplatin sensitivity in both intrinsically resistant organoids and cell lines with acquired resistance.Together,our study identifies a marker gene panel for HR-proficient patients and reveals a broader application of PARP inhibitor/cisplatin in cancer therapy. | Chao Zhang Qiang Guo Lifeng Chen Zheming Wu Xiao-Jian Yan Chengyang Zou Qiuxue Zhang Jiahong Tan Tian Fang Qunxian Rao Yang Li Shizhen Shen Min Deng Liewei Wang Huanyao Gao Jia Yu Hu Li Cheng Zhang Somaira Nowsheen Jake Kloeber Fei Zhao Ping Yin Chunbo Teng Zhongqiu Lin Kun Song Shuzhong Yao Liangqing Yao Lingying Wu Yong Zhang Xiaodong Cheng Qinglei Gao Jian Yuan Zhenkun Lou Jin-San Zhang | 2023 | Signal Transduction and Targeted Therapy2023，8，6： | 0 |
| 13 | Primary Malignant Amelanotic Melanoma in the Female Genital Tract:A Report of Six Cases and a Review of the Literature显示文摘OBJECTIVE To analyze the clinical characteristics,pathologic diagnosis,treatment and prognosis of amelanotic melanoma in the female genital tract(AMFGT).METHODS The medical records of 6 patients with AMFGT between 1991 and 2006 in our hospital were reviewed.RESULTS Of these cases,4 were preliminarily misdiagnosed as chorioepithelioma,sarcoma,adenocarcinoma or lymphoma.Two patients were determined to have AMFGT preoperatively after positive immunohistochemical staining for both S-100 protein and HMB-45.Specimens removed from all 6 cases were tested for immunohistochemical staining,as well as H&E histochemical stains.S-100 and vimentin were both positive in all patients,and HMB-45 was positive in 3 out of 5 patients.Four patients recurred(at 6,6,12 and 19 months) a er primary treatments.Three patients died(at 13,18 and 19 months) a er the initial diagnosis.CONCLUSION Because of an absence of pigmentation AMFGT is extremely difficult to diagnose.Combined immunohistochemical staining,such as the S-100 protein,HMB-45 and vimentin etc,is important in the evaluation of AMFGT.Correct diagnosis plays a crucial role in the treatment of this disease. | Jusheng An Lingying Wu Bin Li Haizhen Lu Ning Li Shaokang Ma | 2008 | Chinese Journal of Clinical Oncology2008，5，5： | 0 |
| 14 | Sentinel Lymph Node Identification in Endometrial Cancer显示文摘OBJECTIVE To evaluate the feasibility of intra-operativedetection of sentinel lymph nodes (SLN) in the patient withendometrial cancer (EC).METHODS Thirty-one patients with Stage Ⅰ and Ⅱ endometrialcancer, who underwent a hysterectomy and a lymphadenectomy,were enrolled in the study. At laparotomy, methylene blue dyetracer was injected into the subserosal myometrium of corpusuteri at multiple sites, and dye uptake into the lymphatic channelswas observed. The blue nodes which were identified as SLNs weretraced and excised. The other nodes were then removed. All of theexcised nodes were submitted for pathological hematoxylin andeosin (H&E) staining examination.RESULTS Failure of dye uptake occurred in 4 of the 31 cases(12.9%) because of spillage, and no lymphatic coloration wasobserved there. Lymphatic staining was clearly observable as bluedye diffused to the lymphatic channels of the uterine surface andthe infundibulopelvic ligaments in 27 (87.1%) cases. Concurrentcoloration in the pelvic lymphatic vessels was also observed in 22of the 27 patients. The SLNs were identified in 23 of the 27 (85.2%)cases with a lymphatic staining, with a total number of 90 SLNs,and a mean of 3.9 in each case (range, 1-10). Besides one SLN (1.1%)in the para-aortic area, the other 89 (98.9%) were in the nodes ofthe pelvis. The most dense locations of SLNs included obturator in38 (42.2%) and interiliac in 19 (21.1%) cases. In our group, pelviclymphadenectomy was conducted in 27 (87.1%) patients andpelvic nodal sampling in 4 (12.9%). Of the 31 cases, a concurrentabdominal para-aortic lymph node sampling was conducted in7. A total of 926 nodes were harvested, with an average of 39.8 ineach case (range, 14-55). Nodal metastases occurred in 3 patients(9.7%), 2 of them with SLN involvement and the other withoutSLN involvement. Adverse reactions or injury related to the studywas not found.CONCLUSION Application of methylene blue dye is feasible inan intra-operative SLN identification of endometrial cancer. Thetechnology is convenient, safe, and worth further investigation. | Bin Li Lingying Wu Xiaoguang Li wHaizhen Lu Ping Bai Shumin Li Wenhua Zhang Jǖzhen Gao | 2009 | Chinese Journal of Clinical Oncology2009，6，2： | 0 |
| 15 | Analysis of Prognosis and Prognostic Factors of Cervical Adenocarcinoma and Adenosqumous Carcinoma of the Cervix显示文摘OBJECTIVE To analyze clinical characteristics and treatmentmethods of the patients with adenocarcinoma of the uterine cervix(AUC) and adenosquamous carcinoma of the cervix (ASCC). Tocompare the survival time of the patients in 2 groups and analyzethe prognostic factors.METHODS Clinical data of both 123 patients with AUC and32 patients with ASCC treated at the Cancer Hospital, ChineseAcademy of Medical Science (CAMS) & Peking Union MedicalCollege (PUMC), were retrospectively analyzed.RESULTS The median age of the AUC patients was 50 years, andthat of the ASCC patients was 44, P = 0.019. Poorly-differentiated(grade 3) cases accounted for 59.5% of the total ASCC patients,while only 32.5% of the AUC patients were in grade 3, P = 0.002.In 123 AUC patients, relapse or failure of the treatment occurredin 63 of the patients (51.2%), and the median relapse time was6 months (0-59 months). In 32 ASCC patients, relapse or failureof the treatment occurred in 8 of these patients (51.2%), with amedian relapse time of 4.5 months (0-52 months). The overall5-year survival rate of the AUC patients was 49.8%, which wassignificantly lower than that of the ASCC patients (74.1%), P =0.015. The 5-year survival rates of the ASCC patients in Stage Ⅰ-Ⅲwere higher than that of the AUC patients with the same stages.However, statistical significant difference could only be foundamong the patients in Stage Ⅱ, P = 0.006. The 5-year survival ratesof the ASCC patients with various differential grade were higherthan those of the AUC patients with the same differential grade,but statistical significant difference could only be found amongthe patients in the two groups with moderately differentiation,P = 0.039. It was found by Cox regression analysis that onlyclinical stage (P < 0.001) and histological type (P = 0.046) were theindependent prognostic factors.CONCLUSION Clinical stage and histological type were theindependent prognostic factors of the AUC and ASCC patients.The prognosis of ASCC patients is better than that of the AUCpatients. | Guangwen Yuan Lingying Wu Xiaoguang Li Manni Huang | 2009 | Chinese Journal of Clinical Oncology2009，6，2： | 0 |
| 16 | Comparative analysis of ATP-based tumor chemosensitivity assay-directed chemotherapy versus physician-decided chemotherapy in platinum-resistant recurrent ovarian cancer显示文摘Objective The aim of the study was to evaluate the role of ATP-based tumor chemosensitivity assay(ATP-TCA) in patients with platinum-resistant recurrent ovarian cancer(PRROC).Methods A total of 43 patients with PRROC who underwent chemotherapy based on the results of ATPTCA in the Cancer Hospital,Chinese Academy of Medical Sciences were included in the present study.As controls,we selected another 43 patients with PRROC who were treated at the physician's discretion within the same time period and had the same clinical characteristics as the patients in the ATP-TCA group.Logrank test and Cox proportional hazards model were adopted for analysis.Results A total of 86 patients were retrospectively analyzed in the present study.Patients were routinely monitored to evaluate the rate of progression-free survival(PFS).The median follow-up time was 13 months.The PFS for the ATP-TCA and control groups was 5 and 3 months,respectively(P = 0.027).Multivariate analysis showed that the type of treatment was an independent prognostic factor for PFS(P = 0.040;HR:0.623;95% CI:0.313–0.973).Subgroup analysis showed that among patients with a treatmentfree interval(TFI) of ≥ 3 months(n = 50),those in the ATP-TCA group had longer PFS than those in the control group(7 vs 4 months,P = 0.010).Meanwhile,the median PFS of patients who underwent ≤ 2 prior chemotherapy regimens(PCR,n = 52) in the ATP-TCA and control groups was 6 months and 4 months,respectively(P = 0.025).Conclusion ATP-TCA-directed chemotherapy might improve the PFS in PRROC.In particular,the survival benefit from ATP-TCA is higher in patients with a TFI of ≥ 3 months or treated with ≤ 2 PCR. | Ning Li Yutao Gao Wei Zhang Xiaoguang Li Bin Li Haimei Tian Yanfen Li Lingying Wu | 2017 | Oncology and Translational Medicine2017，3，6： | 0 |
| 17 | Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency显示文摘Defects in genes involved in the DNA damage response cause homologous recombination repair deficiency(HRD).HRD is found in a subgroup of cancer patients for several tumor types,and it has a clinical relevance to cancer prevention and therapies.Accumulating evidence has identified HRD as a biomarker for assessing the therapeutic response of tumor cells to poly(ADP-ribose)polymerase inhibitors and platinum-based chemotherapies.Nevertheless,the biology of HRD is complex,and its applications and the benefits of different HRD biomarker assays are controversial.This is primarily due to inconsistencies in HRD assessments and definitions(gene-level tests,genomic scars,mutational signatures,or a combination of these methods)and difficulties in assessing the contribution of each genomic event.Therefore,we aim to review the biological rationale and clinical evidence of HRD as a biomarker.This review provides a blueprint for the standardization and harmonization of HRD assessments. | Wenbin Li Lin Gao Xin Yi Shuangfeng Shi Jie Huang Leming Shi Xiaoyan Zhou Lingying Wu Jianming Ying | 2023 | Genomics, Proteomics & Bioinformatics2023，21，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员